<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674242</url>
  </required_header>
  <id_info>
    <org_study_id>GRASPA-TNBC-2018-02</org_study_id>
    <nct_id>NCT03674242</nct_id>
  </id_info>
  <brief_title>Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)</brief_title>
  <official_title>A Randomized Phase 2/3 Study of Eryaspase in Combination With Gemcitabine and Carboplatin Chemotherapy Versus Chemotherapy Alone for the Treatment of Patients With Metastatic or Locally Recurrent Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ERYtech Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ERYtech Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, randomized, Phase 2/3 study in patients with locally&#xD;
      recurrent or metastatic triple-negative breast cancer (TNBC) with no more than one prior&#xD;
      systemic therapy for locally recurrent or metastatic disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of 2 parts:&#xD;
&#xD;
        -  Part 1 is an open-label, multicenter, randomized Phase 2 exploratory study that will&#xD;
           investigate the clinical activity of the combination of eryaspase and&#xD;
           gemcitabine/carboplatin in patients with locally recurrent or metastatic TNBC. Data&#xD;
           analysis of Part 1 will inform choices for the final design and patient population in&#xD;
           Part 2 (Phase 3 study). Patients recruited into Part 1 will not be included in the&#xD;
           Intent-to-Treat patient (ITT) population of Part 2 of the study.&#xD;
&#xD;
        -  Part 2 will be a randomized Phase 3 study designed to evaluate the efficacy of the&#xD;
           combination of eryaspase and gemcitabine/carboplatin in TNBC patients. The current&#xD;
           protocol will focus on Part 1.&#xD;
&#xD;
      Part 1 is the focus of the current protocol, with a primary endpoint of DCR. DCR data as&#xD;
      determined by an IRR will determine whether or not proceeding to Part 2 is warranted. If so,&#xD;
      Part 2 will be implemented via a major amendment to the protocol. Meanwhile, sites will&#xD;
      remain open with the expectation that Part 2 will be activated&#xD;
&#xD;
      After providing informed consent and completing the screening assessments, patients who meet&#xD;
      all inclusion and no exclusion criteria will be randomized in a 1:1 ratio to one of the&#xD;
      following treatment arms:&#xD;
&#xD;
        -  Arm A (experimental arm): eryaspase 100 U/kg on Days 1 and 8 of combination chemotherapy&#xD;
           with gemcitabine/carboplatin, or&#xD;
&#xD;
        -  Arm B (control arm): gemcitabine/carboplatin combination.&#xD;
&#xD;
      Treatment will continue until objective disease progression, unacceptable toxicity, or the&#xD;
      patient's withdrawal of consent.&#xD;
&#xD;
      A survival follow-up period will include the collection of survival, progression of disease&#xD;
      if applicable, subsequent anti-cancer therapy every 12 weeks (± 1 week)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>1 year after last patient randomized</time_frame>
    <description>To determine whether the addition of eryaspase to gemcitabine and carboplatin improves the disease control rate (DCR) by modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by an independent radiological review (IRR) in patients with locally recurrent or metastatic triple-negative breast cancer (TNBC) compared with chemotherapy alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>1 year after last patient randomized</time_frame>
    <description>To compare the DCR between the two treatment arms as determined by the Investigator's assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 year after last patient randomized.</time_frame>
    <description>To compare the objective response rate (ORR) between the two treatment arms as determined by the independent radiological review (IRR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>1 year after last patient randomized.</time_frame>
    <description>To compare progression-free survival (PFS) between the two treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>1 year after last patient randomized.</time_frame>
    <description>To compare the duration of response (DoR) between the two treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 year after last patient randomized.</time_frame>
    <description>To compare overall survival (OS) between the two treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Collected from time of informed consent until 30 days after last study treatment.</time_frame>
    <description>To evaluate the safety and tolerability of eryaspase in combination with chemotherapy versus chemotherapy alone by assessing the number of patients with treatment emergent adverse events per CTCAE v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response assessed by F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging</measure>
    <time_frame>Collected at baseline and within 3 days of the end of Cycle 1 in all patients.</time_frame>
    <description>To evaluate the change in F-18 fluorodeoxyglucose (FDG) tumor uptake as a predictor of clinical response following one cycle of treatment with eryaspase and chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eryaspase induced immunogenecity</measure>
    <time_frame>Samples will be collected pre-dose at Cycle 1 Day 1 and pre-dose at Cycle 3 Day 1 (each Cycle is 21 days)</time_frame>
    <description>To determine the anti-asparaginase antibodies titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers potentials in predicting eryaspase activity.</measure>
    <time_frame>Tissue samples will be collected at baseline. Blood samples for biomarker analysis will be collected during screening, at Cycle 1 Day 1 and Day 8, and at Day 1 of every second cycle ( each is 21 days) until End of Treatment (EOT) visit.</time_frame>
    <description>To determine DNA, RNA and protein levels present in tumor tissues and blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of eryaspase</measure>
    <time_frame>Samples will be collected the first day (D1) and the eight day (D8) of Cycle 1 and Cycle 3 treatment (each Cycle is 21 days) and at End of treatment (EOT)</time_frame>
    <description>To determine total and plasma asparaginase activity (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of eryaspase</measure>
    <time_frame>Samples will be collected the first day (D1) and the eight day (D8) of Cycle 1 and Cycle 3 treatment (each Cycle is 21 days) and at End of treatment (EOT)</time_frame>
    <description>To determine plasma concentrations of asparagine and glutamine (µmol/L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Eryaspase plus Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eryaspase 100 U/kg dosed at Day 1 and Day 8 of each 3-week cycle in combination with&#xD;
Gemcitabine IV infusion 1000 mg/m2, Day 1 and Day 8.&#xD;
Carboplatin IV infusion at a calculated area under the curve (AUC) of 2.0 (AUC2), Day 1 and Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine plus carboplatin dosed at Day 1 and Day 8 of each 3-week cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eryaspase (L-asparaginase encapsulated in red blood cells)</intervention_name>
    <description>IV infusion 100 U/kg</description>
    <arm_group_label>Eryaspase plus Chemotherapy</arm_group_label>
    <other_name>ERY001, GRASPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV infusion 1000 mg/m2</description>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <arm_group_label>Eryaspase plus Chemotherapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion AUC2</description>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <arm_group_label>Eryaspase plus Chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female or male, 18 years of age or older.&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of invasive breast cancer.&#xD;
&#xD;
          3. Metastatic or locally recurrent inoperable breast cancer with no more than one prior&#xD;
             systemic therapy.&#xD;
&#xD;
          4. Diagnosis (original primary tumor or subsequent relapse) of triple negative breast&#xD;
             cancer, defined as the absence of expression of the following receptors in the primary&#xD;
             and/or metastatic tumor tissue:&#xD;
&#xD;
               -  HER2 protein over-expression and/or gene amplification&#xD;
&#xD;
               -  Estrogen receptor (ER), defined as &lt;1% staining by IHC (2).&#xD;
&#xD;
               -  AND progesterone receptors (PgR), defined as &lt;1% staining by IHC.&#xD;
&#xD;
          5. Measurable lesion(s) per RECIST 1.1.&#xD;
&#xD;
          6. Available archival or fresh tumor tissue.&#xD;
&#xD;
          7. Adequate performance status (PS) score.&#xD;
&#xD;
          8. Life expectancy of &gt;12 weeks according to the Investigator's clinical judgment.&#xD;
&#xD;
          9. Females of childbearing potential must have a negative pregnancy test at screening and&#xD;
             an additional pregnancy test prior to first dose. Females of childbearing potential&#xD;
             must agree to use a highly effective method of contraception during treatment and for&#xD;
             at least 6 months after the last dose of study treatment.&#xD;
&#xD;
         10. Adequate laboratory parameters at baseline (obtained &lt;14 days prior to randomization)&#xD;
&#xD;
         11. Patients must be able to understand and comply with the conditions of the protocol and&#xD;
             must have read and understood the consent form and provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating females.&#xD;
&#xD;
          2. Known BRCA1 or BRCA2 mutation carrier.&#xD;
&#xD;
          3. Bone as the only site of disease.&#xD;
&#xD;
          4. Presence of untreated symptomatic central nervous system (CNS) metastases as&#xD;
             determined by MRI or CT scan performed during screening.&#xD;
&#xD;
          5. Prior radiotherapy to the only area of measurable disease.&#xD;
&#xD;
          6. Prophylactic use of supportive bone-modifying therapy for skeletal-related events&#xD;
             (e.g., bisphosphonate, pamidronate, or denosumab), unless treatment is initiated prior&#xD;
             to or within 7 days after randomization.&#xD;
&#xD;
          7. History of recent clinical pancreatitis, according to revised Atlanta criteria, within&#xD;
             3 months of randomization.&#xD;
&#xD;
          8. Neurosensory neuropathy &gt;Grade 2 at baseline.&#xD;
&#xD;
          9. Known history of infection with human immunodeficiency virus (HIV) and/or active&#xD;
             infection with hepatitis B or hepatitis C.&#xD;
&#xD;
         10. Known hypersensitivity to gemcitabine, platinum compounds or asparaginase.&#xD;
&#xD;
         11. Patients who have received live or live attenuated vaccines within 3 weeks of&#xD;
             randomization.&#xD;
&#xD;
         12. Pre-existing coagulopathy (e.g. hemophilia).&#xD;
&#xD;
         13. History of other malignancies except: adequately treated non-melanoma skin cancer,&#xD;
             curatively treated in situ cancer of the cervix, or other solid tumors curatively&#xD;
             treated with no evidence of disease for &gt;2 years.&#xD;
&#xD;
         14. Any other severe acute or chronic condition/treatments that may increase the risk of&#xD;
             study participation&#xD;
&#xD;
         15. Receiving therapy in a concurrent clinical study. Patients must agree not to&#xD;
             participate in any other interventional clinical studies during their participation in&#xD;
             this trial while on study treatment. Patients taking part in surveys or observational&#xD;
             studies are eligible to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Iman El-Hariry, MD, PhD</last_name>
    <phone>+33 478 788 168</phone>
    <email>iman.elhariry@erytech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Baptiste Bertrand, PhD</last_name>
    <phone>+33 478 781 586</phone>
    <email>jb.bertrand@erytech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wesley Teurfs</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Awada</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christel Fontaine</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi asbl</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc Canon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Henry</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem - Klinikai Kozpont - Onkologiai Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Arkosky</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bacs Kiskun Megyei Korhaz</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt Horvath, MD</last_name>
      <phone>+36304913443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Csoszi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanesa Quiroga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Antolin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serafin Morales</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Izarzugaza</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose A Garcia Saenz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirón Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Angel Quintela</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Cortes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J Salvador Bofill</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

